Vectans Pharma - Transmucosal technology, targeted efficacy, improved compliance

ABOUT VECTANS PHARMA

Vectans Pharma is an international pharmaceutical company bringing a new therapeutic approach with its Lauriad^® technology born of French R&D.

This innovative technology enables targeted and prolonged diffusion of APIs, thus optimizing effectiveness and compliance for the benefit of patients.

Vectans Pharma's portfolio currently comprises two products, Sitavig^® and Loramyc^®, both market-approved by American (FDA), European (EMA) and Japanese (PMDA) health authorities.

Through international licensing agreements, Loramyc^®; is commercialized in the United States, Japan, Italy and France, and Sitavig^®; in the United States and France.

NEWS

Exclusive licensing agreement with m8 Pharmaceuticals

m8 Pharmaceuticals and Vectans Pharma signed an exclusive licensing agreement of Loramyc® (miconazole Lauriad®) for Mexico and Brazil.

Jonathan Cohen promoted Director of Regulatory and Industrial Affairs

” It has been almost a year since Jonathan joined Vectans pharma team. Over the past few months, his professional expertise has been a major asset for our growing international development. I have no doubt that he will assume his new responsibilities with the same efficiency and wish him every…

More news

Vectans Pharma is an international pharmaceutical company bringing a new therapeutic approach with its Lauriad^® technology born of French R&D.

This innovative technology enables targeted and prolonged diffusion of APIs, thus optimizing effectiveness and compliance for the benefit of patients.

Vectans Pharma's portfolio currently comprises two products, Sitavig^® and Loramyc^®, both market-approved by American (FDA), European (EMA) and Japanese (PMDA) health authorities.

Through international licensing agreements, Loramyc^®; is commercialized in the United States, Japan, Italy and France, and Sitavig^®; in the United States and France.

Exclusive licensing agreement with m8 Pharmaceuticals

Jonathan Cohen promoted Director of Regulatory and Industrial Affairs

ABOUT VECTANS PHARMA

SITEMAP

CONTACT

Vectans Pharma is an international pharmaceutical company bringing a new therapeutic approach with its Lauriad® technology born of French R&D.

This innovative technology enables targeted and prolonged diffusion of APIs, thus optimizing effectiveness and compliance for the benefit of patients.

Vectans Pharma's portfolio currently comprises two products, Sitavig® and Loramyc®, both market-approved by American (FDA), European (EMA) and Japanese (PMDA) health authorities.

Through international licensing agreements, Loramyc®; is commercialized in the United States, Japan, Italy and France, and Sitavig®; in the United States and France.

Exclusive licensing agreement with m8 Pharmaceuticals

Jonathan Cohen promoted Director of Regulatory and Industrial Affairs

ABOUT VECTANS PHARMA

SITEMAP

CONTACT

Vectans Pharma is an international pharmaceutical company bringing a new therapeutic approach with its Lauriad^® technology born of French R&D.

Vectans Pharma's portfolio currently comprises two products, Sitavig^® and Loramyc^®, both market-approved by American (FDA), European (EMA) and Japanese (PMDA) health authorities.

Through international licensing agreements, Loramyc^®; is commercialized in the United States, Japan, Italy and France, and Sitavig^®; in the United States and France.